RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration
Dissecting the Therapeutic Mechanism of an Effective Combination Treatment Targeting Neuromuscular Junction Dengeneration and Myosteatosis to Combat Sarcopenia
Chinese University of Hong Kong
200 participants
Jan 12, 2023
INTERVENTIONAL
Conditions
Summary
The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model. The results showed that fat mass could be decreased by \~32%, while histology Oil Red O staining indicated a decrease of fat by almost 60%; in contrast, lean muscle mass increased by \~14%. On muscle strength, combined treatment increased twitch force, tetanic force and grip strength by \~30-66%. These in vivo results are very encouraging and the investigators should explore its potential in clinical translation. As VT and HMB supplement have been commercially available and their compliance rates are satisfactory, they can be translated to clinical application easily. The investigators' next step is to confirm its clinical efficacy, so that sarcopenia becomes a new indication of VT and HMB. The hypothesis is that combined treatment of VT and HMB can retard the progression of sarcopenia in human, in terms of muscle mass, muscle strength and performance.
Eligibility
Inclusion Criteria5
- Subjects aged 60 years or above
- Subjects failed in AWGS algorithm
- skeletal muscle mass by BIA (male at \<7.0 kg/m\^2, female at \<5.7 kg/m\^2), and
- handgrip strength (male at \<28 kg, female at \<18kg), and/or
- gait speed test (\>1m/s)
Exclusion Criteria8
- Subjects with pathological bone diseases
- Subjects with chronic inflammatory condition (e.g. rheumatoid arthritis)
- Subjects with neurological problems
- Subjects receiving regular exercise
- Subjecs who are chair-/bed- bound
- Subjects with malignancy
- Subjects with cardiovascular concern such as with pace-maker in-situ
- Subjects with acute fractures or severe osteoarthritis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
0.3g, 35Hz, 20mins/day, at least 3 times/week
Oral nutritional HMB supplement at 3g/day
Daily protein supplement intake
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05525039